Table 2.
Overall response rates of vindesine and bortezomib regimens.
| vDD (n = 35) | vAD (n = 77) | P-value | VDD (n = 58) | VD (n = 79) | P-value | |
|---|---|---|---|---|---|---|
| CR | 6 (17.1%) | 9 (11.7%) | 0.432 | 28 (48.3%) | 24 (30.4%) | 0.033 |
| ≥VGPR | 9 (25.7%) | 19 (24.7%) | 0.906 | 43 (74.1%) | 45 (57.0%) | 0.038 |
| PR | 14 (40.0%) | 30 (39.0%) | 0.917 | 10 (17.2%) | 22 (27.8%) | 0.147 |
| ORR | 23 (65.7%) | 49 (63.6%) | 0.832 | 53 (91.4%) | 67 (84.8%) | 0.249 |
| SD | 11 (31.4%) | 19 (24.7%) | 0.454 | 3 (5.2%) | 8 (10.1%) | 0.292 |
| PD | 1 (2.9%) | 9 (11.7%) | 0.129 | 2 (3.4%) | 4 (5.1%) | 0.648 |
CR, complete response; ≥VGPR, very good partial response or better; PR, partial response; ORR, overall response rate; SD, stable disease; PD, progressive disease.